The Food and Drug Administration is advising consumers not to purchase or use PAIN FLEX, a product promoted and sold for joint pain on various websites, including Amazon.com and possibly in some retail stores.
Similar Posts
Empower Clinic Services LLC dba Empower Pharma. Houston, TX. 483 issued 12/14/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 12/14/2025
Short Title (70 char) Empower Clinic Services LLC dba Empower Pharma. Houston, TX. 483 issued 12/14/2025
FEI Number 3011887629
Firm Name Empower Clinic Services LLC dba Empower Pharma
Record Type 483Insufflation Unit Recall: Olympus Removes High Flow Insufflation Units
Olympus is removing certain High Flow Insufflation Unit models due to software issues that may lead to overpressure events.Face Rock Creamery LLC Recalls 6oz. Vampire Slayer Garlic Cheddar Because of Possible Health Risk
November 14, 2025, Face Rock Creamery LLC of Bandon, OR is voluntarily recalling 16/6oz. units of Vampire Slayer Garlic Cheddar with a use-by date of 11/04/26 because it has the potential to be contaminated with Listeria monocytogenes, an organism which can cause serious and sometimes fatal infectioFresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection, USP, 20 mg per 2 mL (10 mg per mL), 2 mL Fill in a 2 mL Vial Due to Out-of-Specification Endotoxin Results in Certain Reserve Samples
FOR IMMEDIATE RELEASE – Nov. 6,2025 – LAKE ZURICH, Ill.— Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies is voluntarily recalling three lots (numbers 6133156, 6133194, 6133388) of Famotidine Injection, USP, 20 mgWhat Is the Approval Process for Generic Drugs?
Overview of the FDA review and approval process for generic drugsFDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer’s Disease
The FDA granted supplemental approval to Rexulti (brexpiprazole) oral tablets for the treatment of agitation associated with dementia due to Alzheimer’s disease. This is the first FDA-approved treatment option for this indication.